Ekso Bionics reports Q3 EPS (10c), consensus (10c)

Reports Q3 revenue $4.1M, consensus $5.55M.Sold a total of 33 EksoHealth devices in the third quarter of “The receipt of initial CMS reimbursement through our Durable Medical Equipment Medicare Administrative Contractors or DMEs for our Ekso Indego Personal was a major milestone for us and, importantly, spinal cord injury patients, allowing those covered by Medicare to access the transformative mobility benefits of our Ekso Indego Personal at home and in community settings,” said Scott Davis, the Company’s Chief Executive Officer. “With a growing number of CMS claim submissions in our pipeline, we are actively collaborating with our network of existing neuro-rehabilitation facilities, physicians, and DMEs to lay the groundwork for future sales. Going forward, we remain focused on expanding access to our family of EksoHealth devices across the continuum of care while getting back on pace as procurement cycles with Integrated Delivery Networks or IDNs normalize in the near-term.”2024…